Ocena wpływu chemioterapii na czas przeżycia i wybrane objawy wpływające na jakość życia chorych na niedrobnokomórkowego raka płuca w IIIB i IV stopniu zaawansowania

Introduction: The study presents treatment results of 168 patients with non small cell lung cancer in stage IIIB and IV treated since year 2002 to 2006 in Oncological Center in Cracow. Material and methods: Four regimens of chemotherapy: EP (cisplatin, vepesid), MVP (mitomycin C, vinblastin, cisplatin), PN (cisplatin,vinorelbin) and PG (cisplatin, gemcytabin) were used. Results: Average survival time in group treated with MVP regimen was 7.8 months (median 4.3 months), PG 7.1 months (median 7.3 months), EP 10.2 months (median 7.5 months), PN 14.1 months (median 9.8 months). Differences in median survival time were not significant. Average time to progression in group treated with MVP regimen was 3.5 months (median 2.6 months), PG 5.2 months (median 5.8 months): EP 6.6 months (median 5.2 months), PN 6.7 months (median 5.6 months). Improvement in control of symptoms regarding dyspnea, pain and cough was reached in 60%, 38.7% and 60% of patients respectively. There were no significant differences between chemotherapy regimens regarding improvement in symptoms control. Conclusions: Cisplatin + vinorelbin regimen can be recommended as standard method because of the best treatment results.